Summary
I am a non-clinical biomedical scientist with a multidisciplinary background in cell biology and bioinformatics.
Metabolic alterations occurring in different diseases have been the focus of my work. During my PhD at University of Barcelona (UB), I characterised the contribution of different lipid species, mainly free fatty acids, sphingolipids and cholesterol, in liver pathologies and Alzheimer's disease. During my postdoc at Imperial College I switched to a more holistic approach by using state of the art metabolomics, metagenomics and systems biology to study host-microbiome interactions in neurodevelopmental disorders, and explore the mechanisms by which gut microbiota and its metabolites influence diseases.
Currently, I am part of the BRC Gut Health Theme. I combine different omics (metabolomics, metagenomics) and computational tools to identify novel prognostic biomarkers that could be used to improve patient stratification with respect to clinical outcome and prognosis (remission, gut permeability, inflammation) and to develop and validate new therapies for inflammatory bowel disease (IBD) and other gastrointestinal conditions.